Skip to main content

Outcome of children with IgA vasculitis with nephritis treated with oral immunosuppressive treatment in combination with steroids

In brief

In matched children, added immunosuppression yielded similar kidney remission: 70% vs 66%

In this retrospective study, 70% of children receiving immunosuppressive drugs plus steroids reached kidney remission, compared with 66% receiving steroids alone, after a median 4.7 years. Added treatment was followed by a rapid drop in proteinuria, but did not improve long-term remission; the small study leaves the best role and timing of these drugs uncertain.

Journal
Pediatric nephrology (Berlin, Germany) (Q1)
Published
11 November 2026
Study design
Prospective / inception cohort
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Hélène Armier, Marie-Cécile Perier, Jérôme Harambat, Justine Bacchetta, Stéphanie Clavé, Julie Bernardor, et al.
PMID
43012922
DOI
10.1007/s00467-026-07577-z

Why clinicians should know about it

  • Picked for Nephrology (paper of the day, 12 November 2026): Comparative immunosuppression outcomes in IgA vasculitis nephritis

Abstract

BACKGROUND: IgA vasculitis nephritis (IgAVN) determines long-term kidney prognosis in pediatric IgA vasculitis (IgAV). While corticosteroids (CS) remain standard therapy, the benefit of additional immunosuppressive therapy (IS) remains uncertain. METHODS: We conducted a multicenter retrospective study of children with biopsy-proven IgAVN treated with CS and IS in 14 French pediatric nephrology centers between 2000 and 2019. Outcomes were compared with a 1:1 matched cohort treated with CS alone, matched for age, proteinuria, eGFR, and histological severity. The primary endpoint was kidney remission, defined as urine protein-to-creatinine ratio <30 mg/mmol and eGFR >90 mL/min/1.73 m². RESULTS: Fifty-one children (median age 8.5 years) received IS in addition to CS. After a median follow-up of 4.7 years, 30 (59%) achieved remission and 41% had persistent kidney disease. Proteinuria decreased rapidly after IS initiation. In the matched analysis (33 IS + CS vs. 33 CS-only), remission rates were similar (70% vs. 66%, p = 0.79). Older age and delayed initiation of IS were associated with a lower likelihood of remission. Although IS induced a rapid reduction in proteinuria, no significant difference in long-term remission was observed between groups. CONCLUSIONS: In this pediatric IgAVN cohort, no significant difference in long-term kidney remission was observed between children treated with IS + CS and those treated with CS alone. Given the limited sample size, these findings should be interpreted with caution. Prospective pediatric studies are needed to define the optimal role and timing of IS in IgAVN.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.